A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight
in Young Adults with Schizophrenia, Schizoaffective, or Bipolar I Disorder Who are
Early in Their Illness
Alkermes, Inc
PI: Joseph McEvoy, M.D.
A randomized controlled trial of adjunctive tocilizumab in schizophrenia.
NARSAD Independent Investigator Grant
PI: Brian Miller, MD, PhD, MPH
A randomized controlled trial of adjunctive siltuximab in schizophrenia.
Stanley Medical Research Institute
PI: Brian Miller, MD, PhD, MPH
Insomnia, Autonomic Dysfunction, and Suicidal Ideation in Schizophrenia
Augusta University Pilot Study Research Program
PI: Brian Miller, MD, PhD, MPH
Improving cognition via exercise in schizophrenia
National Institute of Mental Health (NIMH)
PI: Joseph McEvoy, MD
A multicenter, randomized, controlled trial of Brexpiprazole for the treatment of
co-occurring schizophrenia and substance use disorder
Otsuka Pharmaceuticals
PI: Joseph McEvoy, MD
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
National Institute of Mental Health (NIMH)
PI: Joseph McEvoy, MD
Observational Study of LAIs in Schizophrenia
Alkermes, Inc
PI: Joseph McEvoy, M.D.
Phase II, A randomized, double-blind, multiple-dose, placebo-controlled study to evaluate
the safety and efficacy of BIIB104 in subjects with cognitive impairment associated
with schizophrenia
Biogen MA, Inc.
PI: Joseph McEvoy, MD
A randomized controlled trial of adjunctive tocilizumab in schizophrenia.
NARSAD Independent Investigator Grant
PI: Brian Miller, MD, PhD, MPH
A randomized controlled trial of adjunctive siltuximab in schizophrenia.
Stanley Medical Research Institute
PI: Brian Miller, MD, PhD, MPH
Clozapine, Insomnia, Hyperarousal, and Suicide in Schizophrenia
Augusta University Pilot Study Research Program
PI: Brian Miller, MD, PhD, MPH
A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy,
safety, and tolerability of orally administered BI 409306 during a 52-week treatment
period as an early intervention in patients with attenuated psychosis syndrome.
Boehringer Ingelheim Pharmaceuticals, Inc.
PI: Joseph McEvoy, MD
Improving cognition via exercise in schizophrenia
National Institute of Mental Health (NIMH)
PI: Joseph McEvoy, MD
Metformin and Lorcaserin for weight loss in people with schizophrenia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
PI: Joseph McEvoy, MD
A phase II, 12-week, randomized, double-blind, placebo-controlled, parallel study
to evaluate efficacy, safety, tolerability, and pharmacokinetics of the three dose
levels of TAK-831 in adjunctive treatment of adult patients with negative symptoms
of schizophrenia
Millennium Pharmaceuticals, Inc.
PI: Joseph McEvoy, MD
Phase II, A randomized, double-blind, multiple-dose, placebo-controlled study to evaluate
the safety and efficacy of BIIB104 in subjects with cognitive impairment associated
with schizophrenia
Biogen MA, Inc.
PI: Joseph McEvoy, MD